PMID	Groups	Groups definition	Groups remarks	View
34313905	Total cohort			View
34120255	Patients without complications			View
30953271	Surgical margins Positive			View
33240927	Normal weight		BMI	View
33240927	Overweight		BMI	View
33240927	Obese		BMI	View
33029430	LRP			View
33029430	RALRP			View
32748620	ORP			View
32748620	RS-RSRP	retzius-sparing robot-assisted radical prostatectomy		View
32648416	RARP			View
32648416	ORP			View
32257973	LRP			View
30929223				View
32257973	RARP			View
32130477	ORP			View
32130477	RARP			View
31833722	Total		hospital readmission after radical prostatectomy.	View
31833722	No hospital readmission		hospital readmission after radical prostatectomy.	View
31833722	Hospital readmission		hospital readmission after radical prostatectomy.	View
31807424	ORP			View
31807424	LRP			View
31807424	RALRP			View
31603415	RARP			View
30929223				View
31603415	LRP			View
31576266	Group 1 (1-45)		The groups were similar in terms of preoperative clinical features	View
31576266	Group 2 (46-91)		The groups were similar in terms of preoperative clinical features	View
30937294	RARP			View
30937294	LRP			View
30937294	RRP			View
30901171	Tp-RLRP			View
30901171	Ep-RLRP			View
30901171	Ep-LRP			View
29931077	ORP		Before propensity score matching	View
30929223				View
29931077	LRP		Before propensity score matching	View
29931077	RARP		Before propensity score matching	View
29931077	ORP		After propensity score matching	View
29931077	LRP		After propensity score matching	View
29931077	RARP		After propensity score matching	View
29757580	RALP			View
29757580	RRP			View
29594551	IRE	irreversible electroporation		View
29594551	RARP			View
29463975	RRP			View
30891454	group 1	the new detrusorrhaphy technique	Bladder Reconstruction and Detrusorrhaphy Technique.	View
29463975	LRP			View
29463975	RARP			View
29348490	RARP			View
29348490	LRP			View
29348490	ORP			View
29032582	ORP			View
29032582	LRP			View
29032582	RARP			View
28733299	RALP			View
28733299	OP			View
30891454	group 2	standard RARP		View
28733299	LP			View
28662644	RRP			View
28662644	RARP			View
28591934	RRP			View
28591934	RARP			View
27531014	Never		physical activity	View
27531014	Sometimes (1-2 times a week)		physical activity	View
27531014	Often (3-4 times a week)		physical activity	View
27531014	Daily or almost daily (5-7 times a week)		physical activity	View
29264170	RARP			View
30801887	total			View
29264170	RRP			View
26770940	total			View
26770940	No change in frequency of nocturia		the frequency of nocturia	View
26770940	Increased frequency of nocturia		the frequency of nocturia	View
26770940	Decreased frequency of nocturia		the frequency of nocturia	View
26762928	RRP			View
26762928	RARP			View
26762928	All men			View
26279826	Total			View
26279826	RRP		Before adjustment	View
30798475	Group 1	patients with early (≤3 months) pre-surgical latency time recovery		View
26279826	RARP		Before adjustment	View
26279826	RRP		After adjustment	View
26279826	RARP		After adjustment	View
26065923	RARP			View
26065923	ORP			View
25790013	Group 1(ROBOTIC)			View
25790013	Group 2 (OPEN)			View
25770484	ORP			View
25770484	RARP			View
25183452	Open			View
30798475	Group 2	patients with late>3 months or not able to reach pre-surgical latency time recovery		View
25183452	Laparoscopic			View
25183452	MIE-RP			View
25183452	Robot-assisted			View
24912809	RARP			View
24912809	LRP			View
24733797	Total			View
24733797	ORP			View
24733797	RARP			View
24582327	Total			View
24582327	RALP			View
30691961				View
24582327	RRP			View
24255757	RRP			View
24255757	RALP			View
24053198	RARP			View
24053198	RRP			View
24044093	Total			View
24044093	RALP			View
24044093	RRP			View
23485928	ORP			View
23485928	RARP			View
34004044	Standardized information	patients received standardized information about the risk of incontinence after RARP	This cohort functioned as historical control (cohort standardized information)	View
30681267	total			View
23465150	LRP			View
23465150	RALP			View
23451984	RRP			View
23451984	RARP			View
23356747	ORP			View
23356747	RALP			View
23356390	Entire			View
23356390	ORRP			View
23356390	MIRP			View
23356390	RALRP			View
30587172	Recurrence-free			View
23356390	LRP			View
23185666	RALP			View
23185666	RRP			View
23185666	Low-risk group			View
23185666	Intermediate-risk group			View
23185666	High-risk group			View
22949997	RRP			View
22949997	RALP			View
22949997	RRP		Nonobese	View
22949997	RALP		Nonobese	View
30587172	Biochemical Recurrence			View
22949997	RRP		Obese	View
22949997	RALP		Obese	View
22111001	RPP			View
22111001	RRP			View
22111001	RALP			View
22196405	RRP			View
22196405	RARP			View
22196405	VUAS	vesicourethral anastomotic stenosis		View
22196405	No VUAS			View
21044243	RRP			View
30548814	No leakage			View
21044243	LRP			View
21044243	RARP			View
20615888	RALP			View
20615888	RRP			View
20615888	RALP		at −80°C for RALP and RRP tissues used for qPCR	View
20615888	RRP		at −80°C for RALP and RRP tissues used for qPCR	View
20438567	ORP			View
20438567	RALP			View
18585849	total			View
18585849	RRP			View
30548814	Leakage			View
18585849	RALP			View
18585849	Satisfied			View
18585849	Dissatisfied			View
18585849	No regret			View
18585849	Regret			View
25484951	Open			View
25484951	Robotic			View
25484951	Open		Surgeon 1	View
25484951	Robotic		Surgeon 1	View
25484951	Open		Surgeon 2	View
30519744	Total			View
25484951	Robotic		Surgeon 2	View
35252339	Patients < 75 yrs.			View
35252339	Patients ≥75 yrs.			View
35223660	Neoadjuvant HT Group			View
35223660	Non-Neoadjuvant HT Group			View
35136291	Overall			View
35136291	Group A		those with PSA >20 ng/ml being the sole criteria for being high risk	View
35136291	Group B		those with GS ≥8 or ≥ T2c disease and any PSA	View
35063205	HOSO		in the placebo group	View
35063205	MAG-EPA		patients in the ω3 group	View
30519744	negative surgical margins			View
34970758	Total			View
34970758	Non-nerve-sparing RARP			View
34970758	Nerve-sparing RARP			View
34970758	Nerve-sparing RARP with SNR			View
34970758	Nerve-sparing RARP without SNR			View
34970758	Total(PBx )			View
34970758	Total(MRI-PBx)			View
34970758	Nerve-sparing RARP (PBx)			View
34970758	Nerve-sparing RARP (MRI-PBx)			View
27613061	Total			View
30519744	unifocal positive surgical margin			View
33595217	Total			View
33595217	relapsed PSA levels			View
34725727	Total			View
34189707	Total			View
34189707	NSM		negative surgical margins	View
34189707	PSM		positive surgical margins	View
34168525	Group A		Patients with preoperative AMS scores higher than 37 and serum-free testosterone levels lower than 8.5 pg/mL were classified as Group A	View
34168525	Group B		whereas those whose preoperative AMS scores were 37 or lower, or whose serum-free testosterone level were 8.5 pg/mL or higher, were classified as Group B	View
34168525	Total			View
32081564	Total			View
30519744	multifocal positive surgical margins			View
32081564	Positive margin group			View
32081564	Negative margin group			View
34039340	Overall			View
34039340	Low IOM		Internal obturator muscle (IOM) mass Index. >median value (11.47708194 cm2/m2)	View
34039340	High IOM		Internal obturator muscle (IOM) mass Index. <median value (11.47708194 cm2/m3)	View
34039340	≤ Normal		< 23 kg/m2	View
34039340	Overweight		23 kg/m2 ≤ overweight < 25 kg/m2	View
34039340	Obese		25 kg/m2 ≤ obese	View
34028165	All included patients			View
32761408	1		patient number	View
30426256	TR-RALP	RS-RALP		View
32761408	2		patient number	View
32761408	3		patient number	View
32761408	4		patient number	View
32761408	5		patient number	View
32761408	6		patient number	View
32761408	7		patient number	View
32737518	Total			View
30526642	Total			View
33816697	RRP			View
33816697	RALP			View
34004044	Individualized information	patients were included after the introduction of continence prediction tool (CPRED) and received individualized information about the risk of UI after RARP (cohort individualized information)	The institutional review board of the the Netherlands Cancer Institute (NCI) approved the study	View
30426256	RS-RALP	Retzius-sparing RALP		View
34024652	All included patients			View
34024652	pN0 disease			View
34024652	pN1 disease			View
33129868	overall population			View
33129868	Sensitivity (%)		nonorgan-confined disease	View
33129868	Sensitivity (%)		nonorgan-confined disease	View
33129868	PPV (%)		nonorgan-confined disease	View
33129868	NPV (%)		nonorgan-confined disease	View
33079250	Total			View
32972895	Development		patients undergoing RARP at the Canisius Wilhelmina Hospital (CWH), Nijmegen	View
30375062	US-guided PFMT	perioperative pelvic floor muscle training (PFMT)	A team composed of a physiotherapist and a nurse provided the following PFMT regimen at least three times (T1, before RARP; T2, immediately after urethral catheter removal, ie, about 7 days after RARP; T3, 1 month after RARP; Figure 2). The team also provided the patient with a discussion on the anatomy of the pelvic floor and continence mechanism using a leaflet, followed by an individually PFMT augmented with US-guided biofeedback and instruction about home PFMT at T1. The physiotherapist visited the bedside of the patient in the ward and provided a 15-min verbal instruction of PFMT at T2. The team provided PFMT with US-guided biofeedback again at T3. The team also confirmed symptoms and severity of UI and gave instructions about the management of UI. When a patient had severe UI, he received one or two times more US-guided PFMT after 1 month until he had a confidence to contract PFM enough to prevent UI.	View
32972895	Validation 1		patients undergoing RARP at the Hospital Group Twente in Almelo-Hengelo	View
32972895	Validation 2		patients undergoing RARP at the St. Antonius Hospital, Nieuwegein-Utrecht	View
32972895	No EPE at histopathology		Development	View
32972895	EPE at histopathology		Development	View
32972895	No EPE at histopathology		Validation 1	View
32972895	EPE at histopathology		Validation 2	View
32972895	No EPE at histopathology		Validation 2	View
32972895	EPE at histopathology		Validation 3	View
32878251	PSA <7		PSA at Diagnosis (ng/mL)	View
32878251	PSA  7-10		PSA at Diagnosis (ng/mL)	View
30375062	Verbal-PFMT	perioperative pelvic floor muscle training (PFMT)		View
32878251	PSA >10		PSA at Diagnosis (ng/mL)	View
32789599	Total			View
32871139	Total			View
24553487	Conventional pT2			View
24553487	Modified ultradissection pT2			View
28230003	Total			View
28230003	BCR		biochemical recurrence	View
32632897	Total			View
30649377	Total			View
30396982	GP 5 negative			View
30279989	total			View
30396982	Latent GP 5			View
30396982	GP 5			View
32167708	r-PRP			View
29715138	Total			View
29715138	Posterior zone		Prostate site	View
29715138	Transition zone		Prostate site	View
31619029	Total			View
31619029	SBx		standard biopsy	View
31619029	TBx		target biopsy	View
31489241	Population			View
30276864	total			View
31489241	Negative SMs			View
31489241	Focal PSM			View
31489241	Non-focal PSM			View
31489241	SubPopulation		Low-volume surgeons	View
31489241	Negative SMs		Low-volume surgeons	View
31489241	Focal PSM		Low-volume surgeons	View
31489241	Non-focal PSM		Low-volume surgeons	View
31489241	SubPopulation		High-volume surgeons	View
31489241	Negative SMs		High-volume surgeons	View
31489241	Focal PSM		High-volume surgeons	View
32005115	Moderate/poor work ability		The Work Ability Index (WAI). The WAI was developed by a Finnish research group with a 24 items version.	View
31489241	Non-focal PSM		High-volume surgeons	View
31363468	1		patient number	View
31363468	2		patient number	View
31363468	3		patient number	View
31363468	4		patient number	View
31363468	5		patient number	View
31363468	6		patient number	View
31363468	7		patient number	View
31363468	8		patient number	View
31363468	9		patient number	View
32005115	High work ability		The Work Ability Index (WAI). The WAI was developed by a Finnish research group with a 24 items version.	View
31363468	10		patient number	View
31363468	11		patient number	View
34472768	Normal BMI			View
34472768	Overweight			View
34472768	Obese			View
33947348	All cases			View
33947348	Upgrading		ISUP grade upgrading (IGU) was defined as ‘ISUP grade in prostatectomy specimen determined to be higher than that in the biopsy specimen’.	View
33947348	No upgrading			View
30365194	Non‐BCR group			View
30365194	BCR group		biochemical recurrence	View
32005115	Total sample			View
28785191	Total			View
28785191	pGS < 7			View
28785191	pGS > 7			View
29593197	Total			View
29279147	Total			View
29279147	Histological-SVI		seminal vesicle invasion	View
28986636	Total			View
28582632	Overall			View
33878204	PV < 100 cm3		Unmatched cohor	View
33878204	PV≥100 cm3		Unmatched cohor	View
31984644	total			View
33878204	PV < 100 cm3		Matched cohort	View
33878204	PV≥100 cm3		Matched cohort	View
28352618	A: ≥70 yr			View
28352618	B: <70 yr			View
26166967	Total			View
19583731	≥70 years			View
19583731	<70 years			View
32497131	Age < 75 years			View
32497131	Age ≥ 75 years			View
27990424	Total			View
28823768	RARP	robot-assisted radical prostatectomy		View
27990425	Target biopsy only			View
27990426	Random biopsy			View
27630337	All 246 patients			View
27630337	SBx patients		standard untargeted biopsy	View
27630337	TBx patients		targeted prostate biopsy	View
31964956	Total			View
26648678	Group 1		patients had undergone surgery for primary bladder outlet obstruction	View
26648678	Group 2		control group（ patients without a history of prostate surgery with equivalent clinicopathologic characteristics）	View
31287254	Total			View
30606182	< 25 g		Prostate weight measured by TRUS (g)	View
33951669	Group 1: SL	Symptomatic lymphoceles		View
28823768	PGA	partial gland ablation		View
30606182	25-50 g		Prostate weight measured by TRUS (g)	View
30606182	51-75 g		Prostate weight measured by TRUS (g)	View
30606182	> 75 g		Prostate weight measured by TRUS (g)	View
25813692	Non-MRI			View
25813692	MRI			View
25813692	Total(Non-MRI)		Bilateral nerve-sparing surgery	View
25813692	PSM(Non-MRI)		Bilateral nerve-sparing surgery	View
25813692	Total(MRI)		Bilateral nerve-sparing surgery	View
25813692	PSM(MRI)		Bilateral nerve-sparing surgery	View
25813692	Total(Non-MRI)		Unilateral nerve-sparing surgery	View
24314031				View
25813692	PSM(Non-MRI)		Unilateral nerve-sparing surgery	View
25813692	Total(MRI)		Unilateral nerve-sparing surgery	View
25813692	PSM(MRI)		Unilateral nerve-sparing surgery	View
25813692	Total(Non-MRI)		Non-nerve-sparing surgery	View
25813692	PSM(Non-MRI)		Non-nerve-sparing surgery	View
25813692	Total(MRI)		Non-nerve-sparing surgery	View
25813692	PSM(MRI)		Non-nerve-sparing surgery	View
31337353	All patients			View
31337353	Non-CKD			View
31337353	CKD		chronic kidney disease	View
19888970				View
31337353	ESRD		end stage renal disease	View
25275059	Our institution			View
25275059	Referring institution			View
24969055	Total			View
24969055	MRI group		high‑risk PCa patients	View
24969055	Non-MRI group		high‑risk PCa patients	View
23878685	Total			View
23114883	Total			View
29274670	Total			View
29274670	Organ-confined			View
29633374	Group 1	patients underwent PSA screening during a medical checkup (group 1),		View
29274670	Non-organ confined			View
34104636	Non-NADT			View
34104636	NADT		neoadjuvant androgen deprivation therapy	View
34104636	Non-NADT		PCa Non-Low Risk Group	View
34104636	NADT		PCa Non-Low Risk Group	View
27031340	Total Cohort			View
27031340	pN1 Patients			View
26539008	RPP			View
26539008	RRP			View
26539008	MIRP			View
29633374	Group 2	patients underwent PSA testing at a clinical urological practice (group 2).		View
32739147	Total			View
33819496	Group RRP			View
33819496	Group RALP			View
26341038	Total			View
26341038	NLR <2.6		neutrophil-to-lymphocyte ratio	View
26341038	NLR ≥2.6		neutrophil-to-lymphocyte ratio	View
34219063	Total			View
34219063	Group 1		patients without GS upgrading	View
34219063	Group 2		patients with GS upgrading	View
35173071	overall			View
29307683	early group	patients regularly received sildenafil (100mg twice a week for 3 months) immediately after catheter removal		View
30979636	overall	3D group plus Cognitive group		View
30979636	3D group	patients were scheduled for 3D elastic AR RARP		View
30979636	Cognitive group	patients were scheduled for 2D cognitive RARP		View
32883625	Overall			View
				View
24397422	3D group	patients underwent laparoscopic RP using a 3D display system		View
24397422	2D group	underwent laparoscopic RP using a 2D display system		View
34410984	PD	patient with Pelvic drain		View
34410984	ND	patient without Pelvic drain		View
34332759	Overall			View
29307683	delayed group	only at 3 months after NS-RALP		View
34332759	AR-3D guided IFS RARP	patients referred to AR-3D guided RARP		View
34332759	mpMRI guided RARP	patients undergoing mpMRI guided RARP		View
34131882	overall			View
34131882	overall			View
33965288	overall			View
33585117	Overall Cohort			View
33585117	Overall Cohort			View
33585117	SDD	SDD patients		View
33585117	SDD			View
33585117	Inpatient	inpatient patients		View
29196816	Experimental group		extended nursing group (experimental group)	View
33585117	Inpatient			View
33380323	RALP	consecutive male patients (study group) who underwent robot-assisted radical prostatectomy		View
33380323	RAPN	consecutive male patients undergoing robot-assisted partial nephrectomy		View
33248139	Anticoagulant group	continued use of any anticoagulant		View
33248139	Thienopyridine group	antiplatelet therapy including any thienopyridine type		View
33248139	Aspirin group	acetylsalicylic acid monotherapy		View
33248139	Control group	Patients without recent antithrombotic therapy		View
32945234	Group A	patients who received bilateral TAP block		View
32945234	Group B	patients who did not received TAP block		View
32929627	Total			View
29196816	Control group			View
32929627	No drain	patients who had their RP performed by two surgeons (PMP and MEA) who generally deferred drain placement unless intraoperatively indicated based on clinical judgement		View
32929627	Drain	patients treated by the remaining seven surgeons who routinely placed pelvic drains.		View
32362599	PSM	PSM was conffrmed in 108 (39.9%) patient		View
32362599	NSM	NSM in 163 (60.1%) patients		View
32362599	Total			View
32174775	VA group	those who received volatile anesthesia		View
32174775	TIVA group	those who received total intravenous anesthesia		View
32164666	Overall			View
32065277	Inpatient cohort	25 in the inpatient cohort		View
32065277	SDD cohort	27 in the SDD cohort		View
29195014	Overall			View
29124889	Non-NeuroSAFE	RALPs NS RALPs without NeuroSAFE		View
29124889	NeuroSAFE	NeuroSAFE RALPs		View
23415965	FS Neg	a negative frozen section result		View
23415965	FS Pos	a postive frozen section result		View
31506877	Conventional ventilation (CV)	control group with CV with a TV of 10 ml per kg of IBW and a PEEP of 4 cmH 2O		View
31506877	Lung protective ventilation (LPV)	intervention group with LPV with a TV of 6 ml per kg of Ideal Body Weight (IBW) and a PEEP of 10 cmH2O		View
31306669	overall			View
31014320	Bilateral nerve-sparing RARP With HA/CMC	46 patients who underwent bilateral nerve-sparing surgery, HA/CMC was used in 13/46 patients (28.3%) undergoing bilateral nerve-sparing RARP		View
31014320	Bilateral nerve-sparing RARP Without HA/CMC	46 patients who underwent bilateral nerve-sparing surgery, 33 patients without HA/CMC		View
31014320	Unilateral nerve-sparing RARP With HA/CMC	137 patients who received unilateral nerve-sparing surgery, 40/137 patients (29.2%) receiving unilateral nerve-sparing RARP		View
33951669	Group 2: no SL	Symptomatic lymphoceles		View
29195014	ORP			View
31014320	Unilateral nerve-sparing RARP Without HA/CMC	137 patients who received unilateral nerve-sparing surgery, 97 patients wothout HA/CMC		View
30868938	Group H + WB	received warmed and humidified CO2 insufflation with the HumiGard device, along with the hot air warming blanket routinely used in our institution		View
30868938	Group WB	received standard CO2 insufflation, along with the hot air warming blanket routinely used in our institution		View
30653808	15 mmHg	at an insufflation pressure of 15 mmHg, giving a total of 600 cases		View
30653808	6 mmHg	at an abdominal insufflation pressure of 6 mmHg, with the previous 300 consecutive RALPs performed		View
30652509	Group 1 - Non-TAP	101 received local anesthetic port infiltration		View
30652509	Group 2 - TAP	105 robot-assisted TAP block		View
30248343	Total	Data pre-VTP		View
30248343		Data pre-PR		View
30248343	Robot assisted surgery			View
29195014	RARP			View
30248343	Laparoscopic surgery			View
30248343	Open surgery			View
29953025	Before propensity score matching, No-mannitol group			View
29953025	Before propensity score matching, Mannitol group			View
29953025	After propensity score matching, No-mannitol group			View
29953025	After propensity score matching, Mannitol group			View
29925316	All patients			View
29925316	Propofol group	groups receiving propofol		View
29925316	Sevoflurane group	groups receiving sevoflurane		View
29415565	Total			View
29086019	Total			View
34789219	Total			View
29188199	25-degree Trendelenburg position	Trendelenburg position with the head down at 25 degrees		View
29188199	30-degree Trendelenburg position	Trendelenburg position with the head down at 30 degrees		View
27758147	Group 1	same-day discharge offered		View
27758147	Group 2	same-day discharge not offered		View
29177945	Total			View
27225958	Retropubic radical prostatectomy			View
27225958	Robotic-assisted laparoscopic prostatectomy			View
27225958	Low PEEP (0-1)			View
27225958	High PEEP (4-5)			View
29052761	Low risk	D’Amico risk group		View
27225958	Low PEEP (0-1)			View
27225958	High PEEP (4-5)			View
26531205	SD group	patients receiving side docking		View
26531205	TD group	patients receiving traditional docking		View
25906167	VF defect (-)	VF defect: Visual field defect after robot-assisted laparoscopic radical prostatectomy		View
25906167	VF defect (+)			View
25906167	Total			View
34748059	Intratumoral			View
34748059	Intraprostatic			View
25129475	TIVA-TCI	receive TIVA-TCI anaesthesia prior to surgery		View
29052761	Intermediate risk	D’Amico risk group		View
25129475	BAL	receive BAL anaesthesia prior to surgery		View
25129475	TIVA-TCI LRP			View
25129475	TIVA-TCI RALP			View
25129475	BAL LRP			View
25129475	BAL RALP			View
24428586	ORP	111,361 (63.4%) patients had ORP (open radical prostatectomy)		View
24428586	LRP	patients had laparoscopic robotic prostatectomy (LRP)		View
24428586	RARP	61,656 (35.1%) patients had RARP (robot-assisted radical prostatectomy)		View
24089234	Group 1	consisted of patients on whom systematic IFS was per- formed		View
24089234	Group 2	consisted of patients on whom IFS was not performed		View
29052761	High risk	D’Amico risk group		View
22967208	Active			View
22967208	Placebo			View
22966792	Total			View
21902975	group 1	in the standard lithotomy position		View
21902975	group 2	in slight trendelenburg position with the robot at the side of the bed - “side-docked.”		View
28872774	Arm I, ND	patient with no drain placement		View
28872774	Arm II, PD	patient with a pelvic drain		View
24440236	UC	urethral catheter		View
24440236	SPT	suprapubic tube		View
22177263	Total			View
28718690				View
35475154	Overall		the surgeon‐assessed operative difficulty.	View
35475154	Optimal difficulty		the surgeon‐assessed operative difficulty.	View
35475154	Suboptimal difficulty		the surgeon‐assessed operative difficulty.	View
35474722	All patients	Preserved urethral length (PUL) was semi‐quantitatively measured using the lateral width of a 16‐Fr urethral balloon catheter while cutting the urethra on a video screen.		View
35474722	Patients with PUL < 16 mm	Preserved urethral length (PUL) was semi‐quantitatively measured using the lateral width of a 16‐Fr urethral balloon catheter while cutting the urethra on a video screen.		View
35474722	Patients with PUL ≥ 16 mm	Preserved urethral length (PUL) was semi‐quantitatively measured using the lateral width of a 16‐Fr urethral balloon catheter while cutting the urethra on a video screen.		View
35116647	ALL			View
35116647	LCM	Ligating clip migration (LCM)	The patients defined as LCM-positive were confirmed to have undergone RARP and subsequently presented to our outpatient clinic with lower urinary tract symptoms (LUTS) or urinary retention, and they were finally diagnosed with clip migration using cystoscopy.	View
35116647	No LCM	Ligating clip migration (LCM)	Otherwise, patients were defined as LCM-negative.	View
34430418	ALL			View
28687029	total			View
34401332	Total			View
34401332	Group A	Group A included patients for whom a standard RARP was performed		View
34401332	Group B	Group B included patients for whom a puboprostatic ligament-sparing RARP was performed.		View
34387037	Total			View
34387037	RARP	radiation therapy		View
34387037	RT	radiation therapy		View
34337474	RS-RARP	Retzius-sparing robotic-assisted radical prostatectomy		View
34337474	S-RARP	standard robotic-assisted radical prostatectomy		View
34279470	SCE (−)	Subcutaneous emphysema（-）		View
34279470	SCE (+)	Subcutaneous emphysema（+）		View
28687029	With metabolic syndrome			View
34211768	Patient1			View
34211768	Patient2			View
34211768	Patient3			View
34211768	Patient4			View
34211768	Patient5			View
34211768	Patient6			View
34211768	Patient7			View
34186136	S-RALP	salvage robotic-assisted laparoscopic radical prostatectomy (S-RALP)		View
34186136	pRALP	primary robotic-assisted laparoscopic radical prostatectomy		View
34168526	Pneumoperitoneum pressure 12 mm Hg			View
28687029	Without metabolic syndrome			View
34168526	Pneumoperitoneum pressure 15 mm Hg			View
34145537	SP group	The da Vinci® single-port (SP)		View
34145537	Xi group	The da Vinci® multiport (Xi)		View
34135173	SP group	single-port		View
34135173	MP group	multiport		View
35929873	13-15mmHg		Insufflation Pressures	View
35929873	6mmHg		Insufflation Pressures	View
33917705	total	patients who underwent surgery		View
33672650	total			View
33672650	NLR < 2.0	NLR = neutrophil-to-lymphocyte ratio		View
33879394	Group 1	from September 2016 to December 2017		View
28677091	Group A	Not Floseal		View
33672650	NLR ≥ 2.0	NLR = neutrophil-to-lymphocyte ratio		View
33672650	PLR < 118	PLR = platelet-to-lymphocyte ratio		View
33672650	PLR ≥ 118	PLR = platelet-to-lymphocyte ratio		View
33672650	LMR < 5.0	LMR = lymphocyte-to-monocyte ratio		View
33672650	LMR ≥ 5.0	LMR = lymphocyte-to-monocyte ratio		View
33672650	0	Systemic Inflammatory Markers		View
33672650	1	Systemic Inflammatory Markers		View
33672650	2	Systemic Inflammatory Markers		View
33672650	3	Systemic Inflammatory Markers		View
33644166	BCR group			View
28677091	Group B	Floseal		View
33644166	Non-BCR group			View
33574414	total			View
33569279	Experimental group			View
33569279	Control group			View
33513885	Nonrobotic RP			View
33513885	Robotic RP			View
33396327	Open RP			View
33396327	Laparoscopic RP			View
33396327	Robotic RP			View
33289056	total			View
28483330	Anterior RARP approach			View
33057938	Without suspension			View
33057938	With suspension			View
33008371	hernia group			View
33008371	no-hernia group			View
33008371	total			View
32738549	Total			View
32738549	RRP			View
32738549	RARP			View
32674608	Group 1			View
32674608	Group 2			View
28483330	Posterior RARP approach			View
32551332	No Transfusion			View
32551332	Transfusion			View
35474865	NRS < 5			View
35474865	NRS ≥ 5			View
32055475	caVUS			View
32055475	Non-caVUS			View
32015914	total			View
33705635	Open		After propensity weighting	View
33705635	Minimally invasive		After propensity weighting	View
35475154	Overall		the surgeon‐assessed operative difficulty.	View
28462944	total			View
35475154	Optimal difficulty		the surgeon‐assessed operative difficulty.	View
35475154	Suboptimal difficulty		the surgeon‐assessed operative difficulty.	View
35474722	All patients	Preserved urethral length (PUL) was semi‐quantitatively measured using the lateral width of a 16‐Fr urethral balloon catheter while cutting the urethra on a video screen.		View
35474722	Patients with PUL < 16 mm	Preserved urethral length (PUL) was semi‐quantitatively measured using the lateral width of a 16‐Fr urethral balloon catheter while cutting the urethra on a video screen.		View
35474722	Patients with PUL ≥ 16 mm	Preserved urethral length (PUL) was semi‐quantitatively measured using the lateral width of a 16‐Fr urethral balloon catheter while cutting the urethra on a video screen.		View
35116647	ALL			View
35116647	LCM	Ligating clip migration (LCM)	The patients defined as LCM-positive were confirmed to have undergone RARP and subsequently presented to our outpatient clinic with lower urinary tract symptoms (LUTS) or urinary retention, and they were finally diagnosed with clip migration using cystoscopy.	View
35116647	No LCM	Ligating clip migration (LCM)	Otherwise, patients were defined as LCM-negative.	View
34430418	ALL			View
34401332	Total			View
28425193	AS	active surveillance		View
34401332	Group A	Group A included patients for whom a standard RARP was performed		View
34401332	Group B	Group B included patients for whom a puboprostatic ligament-sparing RARP was performed.		View
34387037	Total			View
34387037	RARP	radiation therapy		View
34387037	RT	radiation therapy		View
25484948	Age < 50			View
25484948	Age 50-59			View
25484948	Age ≥ 60			View
25484950	Bipolar	Series 1 utilized selective bipolar cautery with the dissection of the neurovascular bundles beginning at the posterior aspect of the prostate and continuing with selective bipolar and sharp dissection caudally for nerve sparing.	RARP Nerve-sparing technique	View
25484950	Athermal clip and peel	Series 2 used an athermal “clip and peel” posterior dissection technique whereby the initial plane was again developed along the posterior aspect of the prostate. In this series Weck hemoclips and sharp dissection alone were used for the initial dissection of the neurovascular bundles off the prostate without any use of cautery. The plane was then continued caudally, using mostly blunt dissection, peeling the neurovascular bundle away from the prostate.	RARP Nerve-sparing technique	View
28425193	BT	brachytherapy		View
25484950	Athermal anterior/posterior	Series 3 used an athermal technique that included the dissection of the lateral prostatic fascia with the neurovascular bundles. For this series, a combined anterior and posterior dissection technique was used in which Weck clips and sharp dissection were applied without the use of cautery and with minimal blunt dissection.	RARP Nerve-sparing technique	View
25484965	No Leakage			View
25484965	Leakage			View
17651548	Overall			View
17651548	First 70			View
17651548	Second 70			View
17893904	Overall			View
25484981	Normal	BMI < 25	Subjects were divided into four categories according to preoperative BMI (kg/m2): normal (BMI < 25), overweight (BMI 25-29.9), mildly obese (BMI 30-34.9), and severely obese (BMI > 35)	View
25484981	Overweight	BMI 25-29.9	Subjects were divided into four categories according to preoperative BMI (kg/m2): normal (BMI < 25), overweight (BMI 25-29.9), mildly obese (BMI 30-34.9), and severely obese (BMI > 35)	View
25484981	Mildly obese	BMI 30-34.9	Subjects were divided into four categories according to preoperative BMI (kg/m2): normal (BMI < 25), overweight (BMI 25-29.9), mildly obese (BMI 30-34.9), and severely obese (BMI > 35)	View
28425193	CA	cryoablation		View
25484981	Severely obese	BMI 35+	Subjects were divided into four categories according to preoperative BMI (kg/m2): normal (BMI < 25), overweight (BMI 25-29.9), mildly obese (BMI 30-34.9), and severely obese (BMI > 35)	View
18246641	Normal	normal (BMI range, 18 to 24.9)		View
18246641	Overweight	overweight (BMI range, 25 to 29.9)		View
18246641	Obese	obese (BMI>30)		View
18435807	total			View
20708781	<50	Prostate size (gm)		View
20708781	50-100	Prostate size (gm)		View
20708781	>100	Prostate size (gm)		View
21165525	total			View
26579289	Overall			View
28425193	ADT	androgen_x0002_deprivation therapy		View
26579289	⩽50	Prostate weight, grams		View
26579289	50-80	Prostate weight, grams		View
26579289	>80	Prostate weight, grams		View
21902974	total			View
22170893	Intraperitoneal	Surgical approach		View
22170893	Extraperitoneal	Surgical approach		View
23000849	total	sRALP		View
23318071	Negative Margin			View
23318071	Positive Margin			View
23318071	All Patients			View
28425193	ORP	open radical prostatectomy		View
24917775	Group 1	ase 1-100		View
24917775	Group 2	case 101-200		View
24917775	Group 3	case 201-300		View
26328083	Negative	Surgical margin		View
26328083	Positive	Surgical margin		View
24223399	RRR	radical retropubic prostatectomy		View
24223399	RALP	Robotic-assisted laparoscopic prostatectomy		View
24454607	ORP (Open)	open radical prostatectomy		View
24454607	RALRP (Robotic)	robotic-assisted laparoscopic radical prostatectomy		View
25032194	Group 1 TURP=yes	16 patients (8%) had received previous TURP		View
33879394	Group 2	from January 2018 onwards		View
28425193	RALP	robot-assisted laparoscopic prostatectomy		View
25032194	Group 2 TURP=no	184 patients (92%) had not		View
25879548	BCR(+)			View
25879548	BCR(−)			View
25927060	RARP			View
25927060	LRP			View
26343985	RALP	robotic assisted radical prostatectomy		View
26343985	RRP	open radical prostatectomy		View
26416058	all			View
27123326				View
27347619	Robotic	robot-assisted laparoscopic approach		View
28425193	EBRT	external beam radiation		View
27347619	Open			View
27622285	Prior surgery	the prior abdominal surgery		View
27622285	No prior surgery	no prior abdominal surgery groups		View
28128908	BT	low-dose rate brachytherapy		View
28128908	DV	Da Vinci prostatectomies DV		View
28488986	Continued smoking			View
28488986	Quit smoking			View
28743170	total			View
28798829	Low-risk	D’Amico risk groups		View
28798829	Intermediate-risk	D’Amico risk groups		View
28425193	Total			View
28798829	High-risk	D’Amico risk groups		View
36118377	total			View
36118377	EPE	extraprostatic extension		View
36118377	No EPE	no extraprostatic extension		View
29128577	Overall			View
29128577	No BCR			View
29128577	BCR			View
29440957	Age> 65 years (Group 1)	99 patients were older than 65 years and underwent robotic radical prostatectomy in one department (group 1)		View
29440957	Age < 50 years (Group 2)	103 patients were younger than 50 years and underwent robotic radical prostatectomy in another department (group 2)		View
29991233	all			View
28130703	LRP			View
30011984	Total			View
30011984	Open			View
30011984	Laparoscopic			View
30011984	Robot			View
30182076	total			View
30182076	Open			View
30182076	Robot-assisted			View
30325603	with BCR			View
30325603	without BCR			View
30332593	total			View
28130703	RARP			View
30521164	Group 1	The first surgeon (MDB) completed 20 consecutive operations in February 2009 - May 2009, with a beginner bedside assistant (Group-1).	a beginner bedside assistant	View
30521164	Group 2	The second surgeon (OA) completed 16 consecutive operations in February 2015 - December 2015, with an experienced (at least 150 cases) bedside assistant (Group-2).	an experienced (at least 150 cases) bedside assistant	View
30978167	r-PRP	Robot-assisted perineal radical prostatectomy (r-PRP)		View
30978167	RARP	Robot-assisted transperitoneal laparoscopic radical prostatectomy (RARP)		View
31450657	Higher Group	174 out of 270 patients showed a bladder neck location above the middle of the pubic symphysis height (higher group)		View
31450657	Lower Group	others showed one below the middle of the pubic symphysis height (lower group)		View
31719716	Physiotherapy	56 men had participated in physiotherapy and had complete data at baseline and 2-year follow-up.	RAC 4 prospectively collects data from participating men at several points in time: approximately 3 weeks or less before their radical prostatectomy and at 3 months, 9 months, 2 years, 3 years, and finally 4 years post-surgery. Pre-surgery and 3 months post-surgery, a full clinical assessment is done by a trained nurse, whereas patient-reported outcomes (PROs) are collected at other time points. These data are entered into a clinical registry, which was used for this study.	View
31719716	No physiotherapy	men who had not participated in physiotherapy		View
31719716	Open prostatectomy			View
31719716	RALP			View
28081352	Total			View
31808399	Group 1	Group 1 included the first fifty cases of a surgeon who had robotic bedside assistance experience (at least 150 cases) between September 2016-July 2018		View
31808399	Group 2	Group 2 included the first fifty cases of a surgeon who had open radical prostatectomy experience (at least 300 cases) but no bedside assistance experience between February 2009-December 2009.		View
31922483	VTE	Venous thromboembolism (VTE) cases developed the condition within 90 days of discharge.		View
31922483	Control	The control group was comprised of patients whose RARP most closely preceded and followed each VTE case in time and who were matched on lymph node dissection and surgeon.		View
28081352	Traction group	Patients were randomized into two groups, A and B, according to whether traction was used or not while removing the specimen. A traction procedure consists of removing the specimen from a small incision. Nontraction procedures remove the specimen from an incision larger than the prostate, which eases the procedure.		View
28081352	Nontraction Group	Patients were randomized into two groups, A and B, according to whether traction was used or not while removing the specimen. A traction procedure consists of removing the specimen from a small incision. Nontraction procedures remove the specimen from an incision larger than the prostate, which eases the procedure.		View
21489117	total			View
34462255	all			View
33663015	Non-PR		After PSM	View
33663952	PLND			View
33423938	pN0			View
33423938	pN1			View
32634854	all			View
32588704	No lymphocele group			View
32588704	Lymphocele group			View
32327264	all	patients treated with robot-assisted radical prostatectomy and superextended pelvic lymph node dissection for prostate cancer		View
32192919	Learning curve surgeons	patients operated on by five younger surgeons in the learning curve (LCSs). LCSs had no previous experience in radical prostatectomy, and the very first RS-RARP procedures of each LCS case are included in the analysis	After matching	View
32192919	Expert surgeons	patients operated by two experienced surgeons (ESs) with >100 procedures	After matching	View
31980875	No hospital readmission			View
33663015	PR		After PSM	View
31980875	Hospital readmission			View
31959548	all			View
31899555	all			View
31727561	Entire cohort			View
31067558	Lymph node invasion-absent			View
31067558	Lymph node invasion-present			View
31067558	Lymph node invasion with Marcille’s Triangle involvement-absent			View
31067558	Lymph node invasion with Marcille’s Triangle involvement-present			View
30398382	Drain placed in the pelvic cavity=yes		control group	View
30398382	Drain placed in the pelvic cavity=no		study grou	View
33551295	Total			View
29767326	ePLND without ICG		control group	View
29767326	ePLND after transrectal injection of ICG		intervention group	View
29737495	Overall			View
29737495	Grade (0-2)	Clavien-Dindo score system		View
29737495	Grade 3 (3a-3b)	Clavien-Dindo score system		View
29472629	Overall			View
29472629	LNI risk <5%	lymph nodes invasion = LNI		View
29472629	LNI risk ≥5%	lymph nodes invasion = LNI		View
29427005	Overall			View
29427005	RRP			View
34313905	Patients with PSM			View
33551295	Urethral fixation	patients operated on with the urethral fixation technique		View
29427005	RARP/LARP			View
29230586	Total			View
29230586	LPLND	lPLND includes the area between the external iliac vein and above the obturator nerve	limited pelvic lymphadenectomy	View
29230586	EPLND	ePLND includes lPLND plus the area below the obturator nerve and on to the internal iliac vessels, plus the proximal common iliac vessel area under the ureter	extended pelvic lymphadenectomy	View
29072565	Q1	Case number		View
29072565	Q2	Case number		View
29072565	Q3	Case number		View
29072565	Q4	Case number		View
29072565	Overall	Case number		View
28905289	None		Group 1 consisted of patients who received no additional treatment	View
33551295	Standard vesicourethral anastomosis	control group		View
28905289	Adjuvant	Adjuvant therapy was defined as secondary treatment (radiation therapy or systemic therapy after prostatectomy) administered with PSA \0.2 ng/ml or before the PSA was drawn, whereas salvage therapy was defined as secondary therapy administered when the PSA C 0.2 ng/ml.	Group 2 patients received adjuvant therapies	View
28905289	Salvage	BCRFS was defined as PSA \0.2 ng/ml. Metastatic recurrence was defined as the first date of strong suspicion of radiographic disease on imaging (computed tomography (CT] magnetic resonance imaging (MRI], or bone scan). These suspicious lesions were not necessarily biopsy confirmed	Group 3 patients received salvage therapies	View
28747519	Overall			View
28747519	ePLND	The ePLND included the removal of the nodes along the external and internal iliac artery and vein, the obturator nodes and the nodes overlying the common iliac vessels up to the ureteral crossing		View
28747519	ePLND+SNB	All SNs were identified using the hybrid tracer indocyanine green-99mTechnetiumnanocolloid (dose: 240 MBq, median particle size: 14 nm), which was trans-rectally injected on the morning of surgery into the peripheral zone of the prostate under ultrasound guidance.		View
28645325	Intermediate-risk	intermediate-risk defined as having at least one characteristic among clinical stage T2b-c or GS of 7 or PSA level of 10 to 20 ng/mL, and 95 patients were classified as high-risk defined as having at least one characteristic among clinical stage ≥ T3a or GS ≥8 or PSA level ≥20 ng/mL, according to the National Comprehensive Cancer Network (NCCN) classification		View
28645325	High-risk	very-high-risk PCa featured by ≥5 cores with a Gleason sum of 8 to10, or multiple NCCN high-risk features were not excluded, and were analyzed as a high-risk group		View
28558990	PLND	Pelvic lymph node dissection (PLND) at the time of radical prostatectomy for low-risk PCa is not recommended by clinical practice guidelines		View
28558990	NO PLND			View
28281741	All patients			View
33495942	Pre-intervention	All patients amongst both groups received preoperative pain management in the form of 1 g of Acetaminophen and a Transverse Abdominis Plane (TAP) block by the Anesthesia Team prior to surgery. No opioids were administered preoperatively. Intraoperative pain control was managed at the discretion of the Anesthesiologist.		View
28281741	SLND	standard PLND (SPLND)	a standard PLND (SPLND) harvesting nodes in the area between the external iliac vessels and above the obturator nerve, plus the area below the obturator nerve	View
28281741	ELND	extended PLND	an EPLND including the areas of the SPLND plus internal iliac vessels area (distally and proximally to the umbilical artery)	View
27981731	Total	underwent robot-assisted sRPLND+PLND		View
27878050	Overall			View
27878050	ORP			View
27878050	RARP			View
30003407	Inpatient RARP	patients who were discharged on postoperative day 1		View
30003407	Outpatient RARP	patients who were discharged on postoperative day 0		View
27544575	Total cohort			View
27544575	Group A	lymphatic vessels were sealed during ePLND at the level of the femoral canal using titanium clips	clips	View
33495942	Post-intervention	Post-operatively, patient’s pain was assessed using standard pain scale scor_x0002_ing and nursing assessments. Prior to protocol implementation, patients were prescribed 5 mg of Oxycodone to use every 4-6 h as needed for pain control. Following institution of non-opioid pain regimen, upon arrival to the inpatient foor, patients were scheduled to receive 1 g of Acetaminophen and 600 mg of Ibuprofen every 6 h and 300 mg of Gabapentin and 5 mg of Oxybutynin every 8 h.		View
27544575	Group B	lymphatic vessels were sealed using bipolar coagulation	no clips	View
26800257	Lymphocele (+)	Symptomatic lymphocele was defined as the presence of any of the following associated with a lymphocele: pelvic pain, leg oedema, hydronephrosis, ileus, deep vein thrombosis or infection/sepsis.		View
26800257	Lymphocele (-)			View
26768422	SN + ePLND	standard fluorescence settings		View
26768422	SN + ePLND, customized settings	customized settings		View
26742982	total			View
26531111	total			View
26531111	Prolonged OR	A total of 57 patients were considered to have a prolonged operative time	prolonged operative time, was prospectively defined as greater than one standard deviation	View
26531111	Not prolonged			View
26502293	Total			View
25216924				View
26502293	A mentor			View
26502293	New surgeons with a mentor			View
25899767	Overall			View
25899767	Lymph nodes present in APFP			View
25899767	Lymph nodes absent in APFP			View
25443913	Overall			View
25443913	Group 1	Cases (1-59)		View
25443913	Group 2	Cases (60-117)		View
25443913	Group 3	Cases (118-175)		View
25443913	Group 4	Cases (176-233)		View
27637685				View
25325024	High-risk	PSA≥20 ng/mL or a biopsy Gleason 8-10 or a cT3a disease		View
25325024	Very high-risk	≥cT3b or cN1 disease		View
25038184	All			View
25038184	LN (-)			View
25038184	LN(+)	LN metastases		View
24964296	All patients			View
24964296	MI-PLND	minimally invasive pelvic lymph node dissection		View
24964296	O-PLND	open pelvic lymph node dissection		View
24411705	Total			View
24411705	ORP			View
27628466				View
24411705	RARP			View
24006951	Overall			View
24006951	LN-			View
24006951	LN+	patients with LN invasion		View
23521086	Total			View
23521086	group 1	lymphocele-positive patients		View
23521086	group 2	non-lymphocele		View
23356436	sLND	standard lymph node dissection	Propensity-score-matched cohort	View
23356436	eLND	extended lymph node dissection	Propensity-score-matched cohort	View
27628473	Macroscopic LN+			View
33267679				View
27628473	Microscopic LN+			View
33997823	Salvage RARP	sRARP after whole gland therapies such as radiotherapy, brachytherapy, and whole gland HIFU, and focal gland therapies such as focal HIFU, cryotherapy, and electroporation.	After matching	View
33997823	RARP			View
22967037	Standard PLND			View
22967037	Extended PLND			View
33912513	Total	underwent SRP		View
33912513	Open	underwent SRP		View
33912513	Robot-Assisted	underwent SRP		View
22834963	LRP			View
22834963	RALP			View
33185707	Overall			View
30790014	Overall			View
28373480	Overall			View
27751731	Group 1	patients (group 1) who underwent sRARP with a UBECM scaffold incorporated into the VUA	a urinary bladder extracellular matrix (UB-ECM) scaffold incorporated into the base of the VUA	View
27751731	Group 2	Group 2 (n = 45) underwent sRARP with standard suturing without use of the graft.		View
27751731	Group 3	Group 3 (control group; n = 45) underwent primary RARP with no graft placement.		View
22556136	Group 1	They were all operated on by an expert in laparoscopy (CV) having performed more than 200 laparoscopic radical prostatec_x0002_tomies prior to transferring his skills to robot-assisted surgery		View
22556136	Group 2	patients who were operated on by a junior surgeon (MR), without previous laparoscopic experience. The junior surgeon had experience in open surgery as he had already performed almost 80 open RP. T		View
31555579	Open sLND			View
31555579	Robotic sLND			View
27600589	Overall			View
33185707	Nerve sparing (+)			View
21851536	Lymph nodes present in anterior lymphofatty tissue ALFT			View
21851536	Lymph nodes absent in lymphofatty tissue ALFT			View
33426579	LigaSure	the LigaSure system		View
33426579	Hem-o-lok	standard surgical clips		View
27628630	RARP			View
27628630	RRR			View
27638369	group 1	patients were included from year 1		View
27638369	group 2	patients from year 2		View
19515403	R-PLND	men (25.6%) who had undergone PLND		View
19515403	No PLND			View
34224165	Total			View
33185707	Nerve sparing (−)			View
19245295	First quarter			View
19245295	Second quarter			View
19245295	Third quarter			View
19245295	Fourth quarter			View
19245295	Total			View
19196060	Quarter 1	July-September		View
19196060	Quarter 2	October-December		View
19196060	Quarter 3	January-March		View
19196060	Quarter 4	April-June		View
18480623	Group A	cases 1-10		View
33112984	TAR group	TAR+TZ sling group		View
18480623	Group B	cases 11-20		View
18480623	Group C	cases 21-41		View
35083274	Dry	“Dry patients” with a loss of urine <2 ml	The average loss of urine in the pad test ranged from 0 to 328 ml.	View
35083274	Wet	“wet patients” with a greater loss	The average loss of urine in the pad test ranged from 0 to 328 ml.	View
35083274	Dry			View
35083274	Wet			View
35083274	Dry			View
35083274	Wet			View
35083274	Dry			View
35083274	Wet			View
33112984	TAR+TZ sling group	a new sling technique using the retrotrigonal muscular layer (TZ sling) combined with total anatomical reconstruction (TAR)		View
35083072	Group A	Group A underwent RARP with mucosal coaptation as a modification	Urethral Mucosal Coaptation RARP	View
35083072	Group B	Group B underwent standard RARP	Standard RARP	View
34692583	Q1	wNVB was defined as the summated value (wNVB = 38.0 +- 6.3 mm) of the following widths at several points.	wNVB (first (Q1) vs. second and third (Q2-3) vs. fourth (Q4) quartile]. The wNVB was 21-34 mm in Q1, 35-41 mm in Q2-3, and 42-59 mm in Q4.	View
34692583	Q2-3	wNVB was defined as the summated value (wNVB = 38.0 +- 6.3 mm) of the following widths at several points.	wNVB (first (Q1) vs. second and third (Q2-3) vs. fourth (Q4) quartile]. The wNVB was 21-34 mm in Q1, 35-41 mm in Q2-3, and 42-59 mm in Q4.	View
34692583	Q4	wNVB was defined as the summated value (wNVB = 38.0 +- 6.3 mm) of the following widths at several points.	wNVB (first (Q1) vs. second and third (Q2-3) vs. fourth (Q4) quartile]. The wNVB was 21-34 mm in Q1, 35-41 mm in Q2-3, and 42-59 mm in Q4.	View
34562303	total			View
34538508	RALP			View
34538508	RRP			View
34384621	Athermal	an athermal technique (AT) using laparoscopic bulldog clamps and suture ligation	RARP+suture	View
34384621	Cautery	the touch cautery (TC) technique should prevent desiccating thermal spread	RARP+suture	View
33064316	Continence group (n = 48)	Continence was defined as pad‐free or the use of safety pads and was confirmed by a 0 ml urinary incontinence volume during the 24‐h pad test and a score of 0 on the second completed ICIQ‐SF questionnaire		View
34337544	non-NS			View
34337544	semi-NS			View
34337544	interfacial NS			View
34337544	intrafascial NS			View
34222808	total	patients who performed RARP with novel bladder neck sparing technique		View
34079768	S-RARP	standard robot-assisted radical prostatectomy	after propensity score matching	View
34079768	T-RARP	transvesical Retzius-sparing robot-assisted radical prostatectomy	after propensity score matching	View
33554284	Standard	da Vinci S		View
33554284	Si	da Vinci Si		View
33554284	Xi	da Vinci Xi		View
33064316	Incontinence group (n = 80			View
33554284	SP	da Vinci SP		View
33474847	total			View
33474847	Non-ED			View
33474847	ED			View
33357994	SP	da Vinci S		View
33357994	Xi	da Vinci Xi		View
33357990	MP-RARP	multiport robot-assisted transperitoneal radical prostatec_x0002_tomy (MP-RARP).		View
33357990	SP-RPP	single-port (SP) robotic surgery		View
33160915	All			View
33160915	MP-RARP	conventional multiport (MP) transperitoneal robot-assisted radical prostatectomy (RARP)		View
26881411				View
33160915	SP-EPP	Pure single-site robot-assisted extraperitoneal prostatectomy (EPP)		View
32931133	NS group	A multistage nerve‐sparing (NS) grade method that involved four approaches to nerve‐preservation, as described previously, was used for function preservation and tumour control in all patients		View
32931133	Non‐NS group			View
32896583	SP-RALRP (Pooled)	Single-port Robot-assisted Radical Prostatectomy		View
32896583	Standard RALRP			View
32631777	Multi-port		RARP	View
32631777	Single-port		RARP	View
32521115	Cut & Suture	Cut and Suture Ligation of the DVC	The DVC is managed after nerve sparing and just prior to urethral transection. The urethra is identified at the lateral aspect after incising the overlying fascial layer. Once this plane is established anterior the urethra, insufflation pressure is increased up to 20 mmHg to minimize venous bleeding. Division of the DVC is performed with cold scissors from lateral to medial direction. Pinpoint bipolar cautery is used to control any arterial bleeding and a 3-0 V Lock suture is then used to ligate the open DVC in a running horseshoe fashion.	View
32521115	Stapler	Endoscopic Stapling of the DVC	Staple control of the DVC was performed using a 45 mm purple load of the Endo-GIA Tri-Stapler (Covidien, North Haven, CT, USA). The instrument is articulated downwards initially to enter below the pubic symphysis. The stapler is then released to neutral position to incorporate the DVC before closure and firing.	View
32521115	Suspension	suture ligation with suspension technique	After incision of the endopelvic fascia, the exposed DVC is ligated just distal to the prostate apex with a single stitch in a figure-8 fashion using 2-0 PDS on a CT 1 needle. A second 2-0 PDS suture is passed through the ligated DVC complex and then through the periosteum of the pubic bone for the anterior suspension. Subsequent steps of the prostatectomy are then performed and the ligated DVC is transected prior to transection of the urethra.	View
32861619	Frail	G8 was assessed at the initial outpatient clinic visit. Patients were categorized into frail (G8 ≤14)		View
34847882	Xi			View
34847882	Si			View
32402143	all	transvesical RARP		View
32158968	all	SP-RARP		View
32158316	Control group		control group	View
32158316	Reconstructive group	the combination of long urethral stump and anterior suspension suture	underwent reconstructive technique	View
33275823	Sexual intercourse		NS RARP	View
33275823	Sexual activity except sexual intercourse		NS RARP	View
33275823	No sexual activity		NS RARP	View
31964317	eBNP	“eBNP” was considered when the length of the spared intraprostatic segment of BN was ⩾1cm (measured by using the length of the branches of the curved robotic scissors as a marker) and the neck diameter was comparable to the diameter of the urethra, that is, not requiring BN reconstruction before anastomosis	bladder neck preservation	View
32861619	Nonfrail	nonfrail (G8 >14) groups		View
31964317	no-BNP	patients who underwent RARP without BNP		View
31929596	group 1	The standard technique of RARP	Standard method	View
31929596	group 2	the surgeries with urethral realignment technique using BNP and MULP techniques	Urethral realignment method	View
31586543	Bladder neck reconstruction	All other cases, where a reduction of the blad_x0002_der neck diameter was performed with the use of additional sutures, were considered as bladder neck reconstructionn. Incase of bladder neck reconstruction, sutures (vicryl 3-0) at 3 and 9 o’clock were placed to reduce the diameter of the bladder neck in a fish-mouth appearance.		View
31586543	Bladder neck sparing	defined when there was no need for a reconstruction using additional sutures of the bladder neck and the circular fibers could be preserved	BNS	View
31579411	NS cohort	nerve sparing (NS) RARP		View
31579411	non-NS cohort			View
31386793	All	Extraperitoneal single-port robot-assisted radical prostatectomy		View
31301693	SP-RALP			View
31257704	SP-RARP			View
25422166	Prior surgery			View
31010600	SP-RARP			View
30697080	ORP	open radical prostatectomy		View
30697080	LRP	laparoscopic radical prostatectomy		View
30697080	RARP	robot-assisted radical prostatectomy		View
30727795	RRP	Retro pubic radical prostatectomy		View
30727795	RALP	Robot assisted laparoscopic radical prostatectomy		View
30041833	all	Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy		View
30021425	eRARP			View
30006861	s-DVC group	standard (s-DVC group)	Standard ligation of DVC: after opening the endopelvic fascia and lateral dissection of prostate up to the apex, a eight-figure 1−0 CT-1 stitch was given, without including pubo-prostatic ligaments; transection of the DVC was postponed at the end of prostatectomy before the section of the urethra	View
30006861	d-DVC group	delayed (d-DVC group) ligation of DVC	Delayed ligation of DVC: at the end of prostatectomy, prior to apex dissection, the DVC was transected; once completed the detachment of prostate, a vertical running suture with 3−0 UR-6 needle, side-to-side, right to left, was given	View
25422166	Non-prior surgery			View
29936567	Men without erectile dysfunction			View
29936567	Men with erectile dysfunction			View
29371819	IIEF‐Q1 score (≥2)			View
29371819	IIEF‐Q1 score (0 or 1)			View
29279663	Standard Dissection			View
29279663	Hydrodissection	The HD technique, including solution type and volume, was adapted from Patel et al for RALP		View
29246146	RARP BNP + PRec	RARP = robot assisted radical prostatectomy, BNP = bladder neck preservation, PRec. =posterior reconstruction		View
29246146	RARP(no BNP+ no PRec.)	RARP = robot assisted radical prostatectomy, BNP = bladder neck preservation, PRec. =posterior reconstruction		View
29246146	Open RRP + BNP	RARP = robot assisted radical prostatectomy, BNP = bladder neck preservation, PRec. =posterior reconstruction		View
29061068	2-layered	the standard 2-layer 2-step PR technique		View
34224165	Non‐BCR			View
29061068	3-layered	the new 3-layer 2-step PR technique using peritoneum		View
18564130	peTRUS-No			View
18564130	peTRUS-Yes	peroperative real-time TRUS (peTRUS)		View
28586158	Continent men			View
28586158	Incontinent men			View
28122393	No NS nerve sparing		Patients matched by propensity score	View
28122393	NS nerve sparing		Patients matched by propensity score	View
27743849	Intussusception	men underwent bladder neck intussusception		View
27743849	Nonintussusception	controls		View
27503582	Controls			View
32696130	Whole Cohort			View
27503582	PUS	posterior urethral suspension		View
26578444	Day 2-Postoperative catheter removal	early catheter removal (48 h after RARP, group A)	Patients includedingroupAunderwent a bladder cystogram 48 h after RARP. If no extravasation of contrast medium was detected, the catheter was removed. The patients were kept in hospital and monitored for24 h.Incaseof spontaneous voiding thepatientsweredischargedonthe 3rd postoperative d (POD) after performing a uroflowmetry. If an anastomotic urinary leakage was detected at cystogram, the catheter was left in place and a cystogram was repeated on the 6th POD. In case of spontaneous voiding, the patients were discharged the day after performing uroflowmetry.	View
26578444	Day 6-Postoperative catheter removal	standard catheter removal (6 d after RARP, group B)	In group B, patients underwent a bladder cystogram 6 d after RARP. Incase of spontaneous voiding,the patients were discharged on the 7th POD after performing a uroflowmetry. If an anastomotic urinary leakage was detected at cystogram, the catheter was left in place, the patient was discharged, and a cystogram was repeated after 7 d.	View
26397733	Kim’s stitch group	The subsequent 60 patients underwent PVC reconstruction with Kim’s stitch and formed the inter_x0002_vention (Kim’s stitch) group.	The only difference between the Kim’s stitch and control groups was the placement of the anterior stitch after the anastomosis.	View
26397733	Control group	70 patients did not undergo PVC reconstruction and formed the control group.		View
25378816	all	RARP		View
24739066	Group A PRAS alone		Group A , in whom posterior urethral reconstruction and anterior suspension (PRAS) was performed	View
24739066	Group B MULP + PRAS			View
24739066	Group C MULP alone	Maximal urethral length preservation	Maximal urethral length preservation (MULP) was first used in RRP and laparoscopic prostatectomy and was shown to ensure early return of continence.	View
24693529	BNC	post-operative bladder neck contracture	BNC was diagnosed by flexible cystoscopy in patients who developed signs and symptoms of bladder outlet obstruction.	View
32696130	BCR-Negative group			View
24693529	No BNC			View
24612011	Matched conventional RALP			View
24612011	Retzius-sparing RALP			View
24166291	CINPT	capsular incision in normal prostatic tissue		View
24166291	No CINPT			View
33550690	AXR-TEP	ambulatory with extended recovery-total extraperitoneal	Ambulatory Surgery With Extended Recovery	View
33550690	IP-TEP	inpatient-total extraperitoneal	Inpatient Surgery n = 20	View
32775266	TP-RALP	Transperitoneal RALP		View
32775266	EP-RALP	extraperitoneal RALP		View
32715451	EP-RALP	extraperitoneal RALP		View
32696130	BCR-Positive group	Patients were considered to have BCR if uPSA ≥ 0.2 ng/mL upon two consecutive rising measurements.		View
32715451	TP-RALP	Transperitoneal RALP		View
30680229	TPRP	transperitoneal laparoscopic approach		View
30680229	RARP	robotassisted (RARP) approach.		View
30680229	ERP	extraperitoneal laparoscopic approach		View
29225060	Anterior RARP			View
29225060	Posterior RARP			View
21992461	retro-apical group	Retro-apical transection of the urethra		View
21992461	anterior-apical group	anterior-apical transection of the urethra		View
22998904	Bladder Neck Sparing			View
22998904	Bladder Neck Nonsparing			View
32639601	ERAS−/PreHab−	Enhanced recovery after surgery (ERAS)/ prehabilitation (PreHab)		View
22738925	INS: intrafascial	Intrafascial nerve-sparing (INS)		View
22738925	Non-INS: inter-/extrafascial, no nerve-sparing	Intrafascial nerve-sparing (INS)		View
21830910	all			View
21620561	Without countertraction	nerve sparing without countertraction (NS-0C)		View
21620561	With countertraction	nerve sparing with countertraction (NS-C)		View
20825759	RALP+Pubovesical Complex-Sparing Technique			View
20863611	Division and selective suturing of dorsal vein complex			View
20863611	Non-selective suturing followed by division of dorsal vein complex			View
20818988	Study group	patients (study group) who underwent this novel self-cinching anas_x0002_tomotic technique using a V-Loc 180 absorbable barbed suture (Covidien, Norwalk, CT) after RARP		View
20818988	Control group	patients (control group) who underwent RARP by the same surgeon before this new technique		View
32639601	ERAS+/PreHab−			View
20801579	Without reconstruction			View
20801579	Posterior reconstruction			View
20626271	all			View
20376897	Rocco	RLRP using the reconstruction of the posterior aspect of the rhabdosphincter (Rocco repair)		View
20376897	Non-Rocco	underwent RLRP prior to the implementation of the Rocco repair were used as the control		View
20362386	No MFRR	the new modified RALP procedure with median fibrous raphe reconstruction		View
20362386	MFRR	the conventional RALP without MFRR		View
19912486	all	patients who underwent bilateral nerve-sparing RALP		View
23675138	all	RALP		View
19195692	No ED			View
32639601	ERAS+/PreHab+	1-day PreHab pro_x0002_gram		View
19195692	ED			View
19178174	Technique 1	patients who underwent apical dissection after cold incision of the dorsal venous complex (DVC) without previous suture ligation	RARP	View
19178174	Technique 2	patients who underwent suture ligation of the DVC before apical dissection.	RAPRP	View
19171418	Continent men			View
19171418	Incontinent men	Men with urine incontinence at 6 mo were significantly less likely to return to baseline score for physical and role functioning, fatigue, financial difficulties, and global health status		View
18419333	Bilateral SNG	t robot-assisted sural-nerve graft (SNG) interposition		View
18419333	Unilateral SNG			View
18419333	Unilateral NS, no SNG			View
18047953	Group 1	routine postoperative cystography operated		View
18047953	Group 2	stopped obtaining routine cystograms for open surgery		View
32591157	Group 1: iPSA level <5.0			View
30054696	DROP-IN probe used in robot-assisted radioguided surgery			View
30054696	DROP-IN probe used in robot-assisted radioguided surgery			View
30054696	DROP-IN probe used in robot-assisted radioguided surgery			View
30054696	DROP-IN probe used in robot-assisted radioguided surgery			View
31673232	prostate cancer group		adenocarcinoma of prostate, underwent robotic assisted radical prostatectomy from 2012 to 2017 at Taichung Veteran General Hospital	View
31673232	non-prostate cancer group		patients were age-matched with PCa ones	View
34268880	patients undergoing robot-assisted radical prostatectomy			View
30143383	Open retropubic radical prostatectomy		surgery based	View
30143383	Robot-assisted laparoscopic radical prostatectomy		surgery based	View
27933389	RRPE	Robot-assisted radical prostatectomy		View
32591157	Group 2: iPSA level 5.0-9.9			View
27933389	ORPE	Retropubic radical prostatectomy		View
27933389	LRPE	Laparoscopic radical prostatectomy		View
27720782	RARP	Robot assisted radical prostatectomy		View
27720782	ORP	open radical prostatectomy		View
27157376	10 th Percentile of Costs < $5,556 per surgery		hospital cost	View
27157376	90 th Percentile of Costs > $18, 621 per surgery		hospital cost	View
25941184	Non-RARP patients		receiving RARP or not	View
25941184	RARP patients		receiving RARP or not	View
22967039	Patients undergoing RALRP		OPERATION	View
22967039	Patients undergoing RRP			View
32591157	Group 3: iPSA level ≥ 10			View
30413390	Early catheter removal POD 3	postoperative day for POD		View
30413390	Standard catheter removal POD 5	postoperative day for POD		View
28153509	Very Low		hospital voloumnn quantile	View
28153509	low		hospital voloumnn quantile	View
28153509	median		hospital voloumnn quantile	View
28153509	high		hospital voloumnn quantile	View
21457071	Premodifications	Trainee adherence to time- oriented surgical goals; use of a dedicated anesthesia team; simultaneous processing by nursing and urology house staff during case turnover; and identification and elimination of unused disposable instruments were the modification		View
21457071	Postmodifications	Trainee adherence to time- oriented surgical goals; use of a dedicated anesthesia team; simultaneous processing by nursing and urology house staff during case turnover; and identification and elimination of unused disposable instruments were the modification		View
28419326	<10 km		Distance to surgical robot (km)	View
28419326	10-29 km		Distance to surgical robot (km)	View
34224165	BCR	The BCR was defined as a postoperative serum PSA level of above 0.2 ng/ml in two consecutive measurements		View
32537666	Age>70		After PSM	View
28419326	>30 km		Distance to surgical robot (km)	View
33359493	High (Score>15)		Decisional Regret Scale score	View
33359493	Low (Score ≤15)		Decisional Regret Scale score	View
28710845	total			View
29789672	CS group	conventional surgery (CS)		View
29789672	FTS group	Fast-track surgery (FTS)		View
31187653	Study group			View
31187653	control group			View
17382723	No. RALP	robot assisted		View
17382723	No. RPP	radical perineal prostatectomy		View
32537666	Age≤70		After PSM	View
17382723	No. RRP	radical retropubic prostatectomy		View
27549566	2006		year	View
27549566	2007		year	View
27549566	2008		year	View
27549566	2009		year	View
27549566	2010		year	View
27549566	2011		year	View
27549566	2012		year	View
27549566	2013		year	View
21717434	Adopter Hospitals		robotic prostatectomy	View
32461073	Overall			View
21717434	Nonadopter Hospitals		robotic prostatectomy	View
34138904	total	Prostate Cancer data Base Sweden (PCBaSe)		View
34692589	group 1	patients undergoing RARP from April 2005 to December 2012	year	View
34692589	group 2	January 2013 to December 2019	year	View
21605514	total			View
21605514	referred by urologist			View
31228477	resident presence group			View
31228477	resident presence group			View
27841089	Patients taking tadalafil			View
27841089	Patients not taking tadalafil			View
32461073	Whole-gland treatment (Total)	patients underwent sRARP after focal or whole-gland primary treatment		View
26955501	total			View
23069384	2000			View
23069384	2008			View
30253389	Very low volume	hospital yearly radical prostatectomy (RP) volume		View
30253389	Low volume	hospital yearly radical prostatectomy (RP) volume		View
30253389	Intermediate volume	hospital yearly radical prostatectomy (RP) volume		View
30253389	High volume	hospital yearly radical prostatectomy (RP) volume		View
32328779	Pentafecta not achieved			View
32328779	Pentafecta achieved			View
28853623	readmission			View
32461073	Focal treatment (Total)	patients underwent sRARP after focal or whole-gland primary treatment		View
28853623	No readmission			View
27083922	LOS = 1	length of hospital stay		View
27083922	LOS>1	length of hospital stay		View
35083069	Total			View
35083069	<120 min	Operative time		View
35083069	120-180 min	Operative time		View
35083069	181-240 min	Operative time		View
35083069	>240 min	Operative time		View
35083069	<2 g/dl	Hb variation		View
35083069	2-4 g/dl	Hb variation		View
32451781				View
35083069	>4 g/dl	Hb variation		View
34876905	Anterior approach			View
34876905	Transvesical approach			View
34876905	Posterior approach			View
34729223	RRP			View
34729223	RARP			View
33604046	Total			View
33604046	4+3	Biopsy Gleason score		View
33604046	4+4	Biopsy Gleason score		View
33604046	Downgrade	Association of characteristics downgraded from biopsy Gleason score 4+4 or 4+3 to ≤3+4 at radical prostatectomy.		View
32378083				View
33604046	No downgrade	Association of characteristics downgraded from biopsy Gleason score 4+4 or 4+3 to ≤3+4 at radical prostatectomy.		View
28261677	Nonupgrade			View
28261677	Upgrade			View
28261677	3+4	Comparison of upgraded Gleason score 6 patients		View
28261677	4+3	Comparison of upgraded Gleason score 6 patients		View
28261677	≥4+4	Comparison of upgraded Gleason score 6 patients		View
25279213	Total			View
34423666	Control group			View
34423666	ERAS group			View
31115364	No	Gleason score upgrade		View
32333202	Total cohort			View
31115364	Yes	Gleason score upgrade		View
33959725	No continence at 3 mo	Demographic characteristics of the cohort with continence recovery status at 3 mo after RARP		View
33959725	Continence at 3 mo	Demographic characteristics of the cohort with continence recovery status at 3 mo after RARP		View
33941161	Minor	Anastomotic urinary leakage after RARP		View
33941161	Major	Anastomotic urinary leakage after RARP		View
33941161	Minor + major	Anastomotic urinary leakage after RARP		View
33941161	Leakage (−)	Anastomotic urinary leakage after RARP		View
33879996	Positive	BCR		View
33879996	Negative	BCR		View
29201511	1st case	Peroperative and postoperative follow-up data		View
32333202	pN1 patients			View
29201511	2nd case	Peroperative and postoperative follow-up data		View
29201511	3rd case	Peroperative and postoperative follow-up data		View
29201511	4th case	Peroperative and postoperative follow-up data		View
29201511	5th case	Peroperative and postoperative follow-up data		View
29201511	6th case	Peroperative and postoperative follow-up data		View
29201511	7th case	Peroperative and postoperative follow-up data		View
29201511	8th case	Peroperative and postoperative follow-up data		View
29201511	9th case	Peroperative and postoperative follow-up data		View
29201511	10th case	Peroperative and postoperative follow-up data		View
29201511	11th case	Peroperative and postoperative follow-up data		View
28253500	Total cohort			View
29201511	12th case	Peroperative and postoperative follow-up data		View
29201511	13th case	Peroperative and postoperative follow-up data		View
29201511	14th case	Peroperative and postoperative follow-up data		View
29201511	15th case	Peroperative and postoperative follow-up data		View
33794533	Whole study group			View
33794533	Pts. without sLC			View
33794533	Pts. with sLC			View
33623874	Group A	Variable		View
33623874	Group B	Variable		View
33552571	Study group			View
21226623	Total			View
27989916	Overall			View
33552571	BMI <30 kg/m2			View
33552571	BMI ≥30 kg/m2			View
33552571	BMI <33.7 kg/m2			View
33552571	BMI ≥33.7 kg/m2			View
33559802	Population			View
33559802	No complications			View
33559802	Postoperative complications			View
33547552	post-RARP			View
33547552	post-RARP + SRT			View
33547552	post-EBRT			View
27989916	Group 1	no previous abdominal surgery		View
33508874	Continence at 3 months			View
33508874	Incontinence at 3 months			View
33508874	Continence at 12 months			View
33508874	Incontinence at 12 months			View
33483790	Exercise group			View
33483790	Usual care			View
22919130	Total			View
33118115	High neuroticism			View
33118115	Low neuroticism			View
33118115	Total sample			View
27989916	Group 2	previous abdominal surgery		View
33102393	Overall			View
33102393	AUR			View
33102393	No AUR			View
31136108				View
32944518	Early			View
32944518	Delayed			View
32944518	Non-LIESWT			View
28054309	Era 2005-2009			View
28054309	Era 2010-2014			View
25024790	Group (median)			View
32219979	Peripheral zone	three cohorts according to the tumour zonal origin described on preoperative magnetic resonance imaging (MRI)		View
22398201	Total			View
32754332	Total			View
32754332	ORP			View
32754332	RARP			View
32564173	RARP			View
32564173	ORP			View
32449896	Total study sample			View
32449896	Peritoneal flap			View
32449896	Control group			View
32420156	<8.70 mm	mRUL		View
32219979	Mixed origin	three cohorts according to the tumour zonal origin described on preoperative magnetic resonance imaging (MRI)		View
32420156	≥8.70 mm	mRUL		View
32420156	<17.79 mm	PSC		View
32420156	≥17.79 mm	PSC		View
32420156	<8.85 mm	LAM		View
32420156	≥8.85 mm	LAM		View
32420156	<19.43 mm	OIM		View
32420156	≥19.43 mm	OIM		View
32420156	<10.42 mm	UWT		View
32420156	≥10.42 mm	UWT		View
25378817	2005-2008	NO.of patients		View
32219979	Transitional zone	three cohorts according to the tumour zonal origin described on preoperative magnetic resonance imaging (MRI)		View
25378817	2009-2010	NO.of patients		View
25378817	2011-2012	NO.of patients		View
32257810	Group 1			View
32257810	Group 2			View
32257810	Group 3			View
32257810	Group 4			View
32257810	Group 5			View
24171923	Total			View
32188426	Continence	1 Month		View
32188426	Incontinence	1 Month		View
32048341	Ophthalmic disease (+) Glaucoma (+)	An expert ophthalmologist examined the eyes before and 7 days after RALP.		View
32188426	Continence	3 Months		View
32188426	Incontinence	3 Months		View
32188426	Continence	6 Months		View
32188426	Incontinence	6 Months		View
32188426	Continence	12 Months		View
32188426	Incontinence	12 Months		View
32188426	Continence	24 Months		View
32188426	Incontinence	24 Months		View
32188426	Continence	48 Months		View
32188426	Incontinence	48 Months		View
32048341	Ophthalmic disease (+) Glaucoma (-)	An expert ophthalmologist examined the eyes before and 7 days after RALP.		View
32005113	Overall			View
31718600	Overall			View
31620590	Total			View
31620590	BCR (-)			View
31620590	BCR (+)			View
31607103	Total			View
31607103	Group 1	Degree of BN elevation		View
31607103	Group 2	Degree of BN elevation		View
31579118	RARP			View
31579118	negative	Surgical margins		View
32048341	Normal			View
31579118	positive	Surgical margins		View
34917689	Total			View
31464649	Total			View
31428576	Total			View
31428576	PSA responder			View
31428576	PSA non-responder			View
31384606	Total			View
31355454	RARP			View
31355454	RRP			View
29349945	Total			View
32048341	Total			View
31249271	≤70 years	2004-2006		View
31249271	>70 years	2004-2006		View
31249271	≤70 years	2007-2009		View
31249271	>70 years	2007-2009		View
31249271	≤70 years	2010-2012		View
31249271	>70 years	2010-2012		View
31148505	Total			View
30975668	Total			View
30946773	Sample			View
30891454	Group 1			View
34155724	Group 1	PSA values measured after 4-to-8 weeks of RARP as pPSA group (PSA ≥0.1 ng/ mL)(Group 1)		View
31893344	Total			View
30891454	Group 2			View
30740014	Valveless Trocar Group			View
30740014	Control Group			View
30587172	Total			View
30587172	Evaluated			View
30587172	Lost to FU			View
30587172	Recurrence-free			View
30587172	Biochemical Recurrence			View
30212952	Total			View
30029714	Moderate/poor work ability			View
31704865	Total			View
30029714	High work ability			View
30029714	Total sample			View
28859491	No APA			View
28859491	APA group			View
28655528	Total			View
28070166	Low and intermediate risk			View
28070166	High risk			View
27777500	Group 1			View
27777500	Group 2			View
27777500	Group 3			View
31673831	Total			View
34970314	LRP			View
34970314	RARP			View
35300134	iPCa			View
35300134	Non-iPCa			View
33082633				View
33082633	Upgraded			View
33082633	Not upgraded			View
32665997	Upgraded			View
32665997	Not upgraded			View
32611411	Pre-HIFU			View
26936203	RRP			View
32611411	Pre-sRARP			View
32158334	RARP			View
32158334	IMRT			View
32158334	LDR			View
32158334	LDR+EBRT			View
30183609	Group 1			View
30183609	Group 2			View
28270949	Low-risk patients			View
28270949	High-risk patients			View
27900214	tumor ⩽ 5 mm			View
26936203	RARP			View
27900214	tumor 5-10 mm			View
27900214	tumor > 10 mm			View
23978277	BT			View
23978277	RALP			View
23978277	AS			View
23225803	RALP			View
23225803	RRP			View
23225803	RT+HT			View
23225803	HT			View
32245911	Radiotherapy			View
26936203	Controls			View
32245911	Prostatectomy			View
31176208	RARP			View
31176208	VMAT			View
28988599	very-low-risk			View
28988599	low-risk			View
20586661	Period I			View
20586661	Period II			View
35083069	Total			View
35083069	<120 min	Operative time		View
35083069	120-180 min	Operative time		View
32720178	All			View
35083069	181-240 min	Operative time		View
35083069	>240 min	Operative time		View
35083069	<2 g/dl	Hb variation		View
35083069	2-4 g/dl	Hb variation		View
35083069	>4 g/dl	Hb variation		View
34876905	Anterior approach			View
34876905	Transvesical approach			View
34876905	Posterior approach			View
34729223	RRP			View
34729223	RARP			View
32720178	Inguinal hernia positive	CT scanning was performed in all patients for cancer stage evaluation		View
33604046	Total			View
33604046	4+3	Biopsy Gleason score		View
33604046	4+4	Biopsy Gleason score		View
33604046	Downgrade	Association of characteristics downgraded from biopsy Gleason score 4+4 or 4+3 to ≤3+4 at radical prostatectomy.		View
33604046	No downgrade	Association of characteristics downgraded from biopsy Gleason score 4+4 or 4+3 to ≤3+4 at radical prostatectomy.		View
28261677	Nonupgrade			View
28261677	Upgrade			View
28261677	3+4	Comparison of upgraded Gleason score 6 patients		View
28261677	4+3	Comparison of upgraded Gleason score 6 patients		View
28261677	≥4+4	Comparison of upgraded Gleason score 6 patients		View
32720178	nguinal hernia negative			View
25279213	Total			View
34423666	Control group			View
34423666	ERAS group			View
34393231	Total			View
31115364	No	Gleason score upgrade		View
31115364	Yes	Gleason score upgrade		View
33959725	No continence at 3 mo	Demographic characteristics of the cohort with continence recovery status at 3 mo after RARP		View
33959725	Continence at 3 mo	Demographic characteristics of the cohort with continence recovery status at 3 mo after RARP		View
33941161	Minor	Anastomotic urinary leakage after RARP		View
33941161	Major	Anastomotic urinary leakage after RARP		View
31538242	Continent	Postoperative ICIQ-Score 0-5 points		View
33941161	Minor + major	Anastomotic urinary leakage after RARP		View
33941161	Leakage (−)	Anastomotic urinary leakage after RARP		View
33879996	Positive	BCR		View
33879996	Negative	BCR		View
29201511	1st case	Peroperative and postoperative follow-up data		View
29201511	2nd case	Peroperative and postoperative follow-up data		View
29201511	3rd case	Peroperative and postoperative follow-up data		View
29201511	4th case	Peroperative and postoperative follow-up data		View
29201511	5th case	Peroperative and postoperative follow-up data		View
29201511	6th case	Peroperative and postoperative follow-up data		View
34155724	Group 2	undetectable PSA group (PSA		View
31538242	Incontinent	Postoperative ICIQ-Score ≥6 points		View
29201511	7th case	Peroperative and postoperative follow-up data		View
29201511	8th case	Peroperative and postoperative follow-up data		View
29201511	9th case	Peroperative and postoperative follow-up data		View
29201511	10th case	Peroperative and postoperative follow-up data		View
29201511	11th case	Peroperative and postoperative follow-up data		View
29201511	12th case	Peroperative and postoperative follow-up data		View
29201511	13th case	Peroperative and postoperative follow-up data		View
29201511	14th case	Peroperative and postoperative follow-up data		View
29201511	15th case	Peroperative and postoperative follow-up data		View
33794533	Whole study group			View
27124625	2005-2008			View
33794533	Pts. without sLC			View
33794533	Pts. with sLC			View
33623874	Group A	Variable		View
33623874	Group B	Variable		View
33552571	Study group			View
33552571	BMI <30 kg/m2			View
33552571	BMI ≥30 kg/m2			View
33552571	BMI <33.7 kg/m2			View
33552571	BMI ≥33.7 kg/m2			View
33559802	Population			View
27124625	2009-2010			View
33559802	No complications			View
33559802	Postoperative complications			View
33547552	post-RARP			View
33547552	post-RARP + SRT			View
33547552	post-EBRT			View
33508874	Continence at 3 months			View
33508874	Incontinence at 3 months			View
33508874	Continence at 12 months			View
33508874	Incontinence at 12 months			View
33483790	Exercise group			View
27124625	2011-2012			View
33483790	Usual care			View
22919130	Total			View
33118115	High neuroticism			View
33118115	Low neuroticism			View
33118115	Total sample			View
33102393	Overall			View
33102393	AUR			View
33102393	No AUR			View
31136108				View
32944518	Early			View
27124625	2013-2015			View
32944518	Delayed			View
32944518	Non-LIESWT			View
28054309	Era 2005-2009			View
28054309	Era 2010-2014			View
25024790	Group (median)			View
22398201	Total			View
32754332	Total			View
32754332	ORP			View
32754332	RARP			View
32564173	RARP			View
27124625	Total			View
32564173	ORP			View
32449896	Total study sample			View
32449896	Peritoneal flap			View
32449896	Control group			View
32420156	<8.70 mm	mRUL		View
32420156	≥8.70 mm	mRUL		View
32420156	<17.79 mm	PSC		View
32420156	≥17.79 mm	PSC		View
32420156	<8.85 mm	LAM		View
32420156	≥8.85 mm	LAM		View
31148505	Total			View
32420156	<19.43 mm	OIM		View
32420156	≥19.43 mm	OIM		View
32420156	<10.42 mm	UWT		View
32420156	≥10.42 mm	UWT		View
25378817	2005-2008	NO.of patients		View
25378817	2009-2010	NO.of patients		View
25378817	2011-2012	NO.of patients		View
32257810	Group 1			View
32257810	Group 2			View
32257810	Group 3			View
31119473	Anterior approach			View
32257810	Group 4			View
32257810	Group 5			View
24171923	Total			View
32188426	Continence	1 Month		View
32188426	Incontinence	1 Month		View
32188426	Continence	3 Months		View
32188426	Incontinence	3 Months		View
32188426	Continence	6 Months		View
32188426	Incontinence	6 Months		View
32188426	Continence	12 Months		View
31119473	Posterior approach			View
32188426	Incontinence	12 Months		View
32188426	Continence	24 Months		View
32188426	Incontinence	24 Months		View
32188426	Continence	48 Months		View
32188426	Incontinence	48 Months		View
32005113	Overall			View
31718600	Overall			View
31620590	Total			View
31620590	BCR (-)			View
31620590	BCR (+)			View
32807046	Total			View
31607103	Total			View
31607103	Group 1	Degree of BN elevation		View
31607103	Group 2	Degree of BN elevation		View
31579118	RARP			View
31579118	negative	Surgical margins		View
31579118	positive	Surgical margins		View
34917689	Total			View
31464649	Total			View
31428576	Total			View
31428576	PSA responder			View
34120255	Patients with complications			View
32807046	Novice	three bedside assistants (ran_x0002_domly distributed throughout the series, based on availa_x0002_bility): one with bedside and console experience, one only with relevant bedside experience, one basically inexperienced.	Before this study the inexperienced bedside assis_x0002_tant didn’t perform any robotic procedure, while the experienced one performed 40 procedures; the bed assis_x0002_tant with console experience performed more than 60 procedure as bed assistant and more than 30 procedure as console surgeon.	View
31428576	PSA non-responder			View
31384606	Total			View
31355454	RARP			View
31355454	RRP			View
29349945	Total			View
31249271	≤70 years	2004-2006		View
31249271	>70 years	2004-2006		View
31249271	≤70 years	2007-2009		View
31249271	>70 years	2007-2009		View
31249271	≤70 years	2010-2012		View
32807046	Experienced	three bedside assistants (ran_x0002_domly distributed throughout the series, based on availa_x0002_bility): one with bedside and console experience, one only with relevant bedside experience, one basically inexperienced.	Before this study the inexperienced bedside assis_x0002_tant didn’t perform any robotic procedure, while the experienced one performed 40 procedures; the bed assis_x0002_tant with console experience performed more than 60 procedure as bed assistant and more than 30 procedure as console surgeon.	View
31249271	>70 years	2010-2012		View
31148505	Total			View
30975668	Total			View
30946773	Sample			View
30891454	Group 1			View
30891454	Group 2			View
30740014	Valveless Trocar Group			View
30740014	Control Group			View
30587172	Total			View
30587172	Evaluated			View
32807046	Console experienced	three bedside assistants (ran_x0002_domly distributed throughout the series, based on availa_x0002_bility): one with bedside and console experience, one only with relevant bedside experience, one basically inexperienced.	Before this study the inexperienced bedside assis_x0002_tant didn’t perform any robotic procedure, while the experienced one performed 40 procedures; the bed assis_x0002_tant with console experience performed more than 60 procedure as bed assistant and more than 30 procedure as console surgeon.	View
30587172	Lost to FU			View
30587172	Recurrence-free			View
30587172	Biochemical Recurrence			View
30212952	Total			View
30029714	Moderate/poor work ability			View
30029714	High work ability			View
30029714	Total sample			View
28859491	No APA			View
28859491	APA group			View
28655528	Total			View
31001870	Total			View
28070166	Low and intermediate risk			View
28070166	High risk			View
27777500	Group 1			View
27777500	Group 2			View
27777500	Group 3			View
34970314	LRP			View
34970314	RARP			View
35300134	iPCa			View
35300134	Non-iPCa			View
33082633				View
30972506	All patients			View
33082633	Upgraded			View
33082633	Not upgraded			View
32665997	Upgraded			View
32665997	Not upgraded			View
32611411	Pre-HIFU			View
32611411	Pre-sRARP			View
32158334	RARP			View
32158334	IMRT			View
32158334	LDR			View
32158334	LDR+EBRT			View
30972506	Low - D’Amico risk classifcation			View
30183609	Group 1			View
30183609	Group 2			View
28270949	Low-risk patients			View
28270949	High-risk patients			View
27900214	tumor ⩽ 5 mm			View
27900214	tumor 5-10 mm			View
27900214	tumor > 10 mm			View
23978277	BT			View
23978277	RALP			View
23978277	AS			View
30972506	Intermediate - D’Amico risk classifcation			View
23225803	RALP			View
23225803	RRP			View
23225803	RT+HT			View
23225803	HT			View
32245911	Radiotherapy			View
32245911	Prostatectomy			View
31176208	RARP			View
31176208	VMAT			View
28988599	very-low-risk			View
28988599	low-risk			View
30972506	High - D’Amico risk classifcation			View
31556779	Total			View
20586661	Period I			View
20586661	Period II			View
34631541	LRP			View
34631541	RARP			View
34432012	ORP			View
34432012	LRP			View
34432012	RARP			View
34337458	RALP			View
34337458	RRP			View
30953271	Total			View
34336234	LRP-NS		in the whole population	View
34336234	RARP-NS		in the whole population	View
34336234	LRP-NS		in the nerve-sparing procedures	View
34336234	RARP-NS		in the nerve-sparing procedures	View
33751413	Total		Prostate volume	View
33751413	RARP		Prostate volume	View
33751413	ORP		Prostate volume	View
33751413	Radiation therapy		Prostate volume	View
33751413	No definitive treatment		Prostate volume	View
33751413	Total cost		Prostate volume	View
30953271	Surgical margins Negative			View
33751413	Hospitalization cost		Prostate volume	View
33751413	Physician visit cost		Prostate volume	View
33751413	Imaging/procedure cost		Prostate volume	View
33650538	Group 1		Prostate volume	View
33650538	Group 2		Prostate volume	View
33437271	ORP		Prostate volume	View
33437271	RARP		Prostate volume	View
33240927	Overall		Prostate volume	View
33240927	≤40cc		Prostate volume	View
33240927	>40cc		Prostate volume	View